Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V, a leading global pharmaceutical company, announced the launch in Canada of three generic products indicated in the treatment of HIV for certain patients. One of the products is Mylan-emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg, a generic alternative to Truvada.

Mylan received final approval from Health Canada for this product and for Mylan-efavirenz/emtricitabine/tenofovir disoproxil fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla; and Mylan-tenofovir disoproxil 300 mg, a generic alternative to Viread.

Mylan's chief commercial officer Tony Mauro said, "Mylan has a strong and sustained commitment to expanding access to treatment for HIV/AIDS and other diseases around the world, and today marks another milestone in those efforts. More than 40% of people worldwide being treated for HIV/AIDS with an antiretroviral depend on a Mylan product every day, and we're proud to further expand access to such medicines in Canada."

Approximately 37 million people globally are living with HIV/AIDS today. As a champion for access, Mylan has invested $250 million in expanding its antiretroviral (ARV) production capacity, enabling the company to produce 4 billion ARV tablets and capsules every year.

Mylan-emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Mylan-efavirenz/emtricitabine/tenofovir disoproxil fumarate 600 mg, 200 mg, and 300 mg is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Mylan-tenofovir disoproxil 300 mg is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients 12 years of age and older and the treatment of chronic hepatitis B infection in adults.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership.

Truvada and Viread are registered trademarks of Gilead Sciences, Inc. or its related companies. Atripla is a registered trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.